CompletedNot Applicable

An Exosomal miRNA-based Liquid Biopsy for ICC Detection

United States535 participantsStarted 2024-06-21

Plain-language summary

Intrahepatic cholangiocarcinoma (ICC) is a malignant liver tumor with poor prognosis and limited curative treatment options. Early and accurate detection remains an unmet clinical need. The LUMIC study aims to develop a non-invasive liquid biopsy platform based on both exosomal microRNAs (exo-miRNAs) to detect intrahepatic cholangiocarcinoma with high sensitivity and specificity.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed intrahepatic cholangiocarcinoma * Availability of pre-treatment plasma sample * Informed consent provided Exclusion Criteria: * Extrahepatic cholangiocarcinoma * History of other malignancy within 5 years * Active infection, autoimmune disease, or pregnancy * Inadequate clinical data or poor sample quality

What they're measuring

Sensitivity

Timeframe: Through study completion (~1 year)

Trial details

NCT IDNCT07225452

SponsorCity of Hope Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-05

View on ClinicalTrials.gov More Intrahepatic Cholangiocarcinoma (Icc) trials